FDA grants orphan-drug status to GenVec's TNFerade
GenVec received orphan-drug designation from the FDA for pancreatic cancer drug TNFerade. "The designation will strengthen the TNFerade program at GenVec by offering potential clinical development and commercialization benefits," CEO Paul Fischer said.
American City Business Journals
| 11/4
This story published in BIO SmartBrief on 11/05/2009
Get stories like these delivered daily for FREE:
|
BIO SmartBrief
Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more |
|